Jeffrey A Berinstein1, Shirley A Cohen-Mekelburg2, Gillian M Greenberg3, Daniel Wray4, Sameer K Berry5, Sameer D Saini2, A Mark Fendrick6, Megan A Adams2, Akbar K Waljee2, Peter D R Higgins5. 1. Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, Michigan; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan. Electronic address: jberinst@med.umich.edu. 2. Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, Michigan; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan; VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan. 3. Department of Pediatrics, Children's Hospital of Michigan, Detroit, Michigan. 4. Twine Clinical Consulting, Park City, Utah. 5. Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, Michigan. 6. Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; Center for Value-Based Insurance Design, University of Michigan, Ann Arbor, Michigan.
Abstract
BACKGROUND: Inflammatory bowel disease (IBD) is associated with substantial symptom burden, variability in clinical outcomes, and high direct costs. We sought to determine if a care coordination-based strategy was effective at improving patient symptom burden and reducing healthcare costs for patients with IBD in the top quintile of predicted healthcare utilization and costs. METHODS: We performed a randomized controlled trial to evaluate the efficacy of a patient-tailored multicomponent care coordination intervention composed of proactive symptom monitoring and care coordinator-triggered algorithms. Enrolled patients with IBD were randomized to usual care or to our care coordination intervention over a 9-month period (April 2019 to January 2020). Primary outcomes included change in patient symptom scores throughout the intervention and IBD-related charges at 12 months. RESULTS: Eligible IBD patients in the top quintile for predicted healthcare utilization and expenditures were identified. A total of 205 patients were enrolled and randomized to our intervention (n = 100) or to usual care (n = 105). Patients in the care coordinator arm demonstrated an improvement in symptoms scores compared with usual care (coefficient, -0.68, 95% confidence interval, -1.18 to -0.18; P = .008) without a significant difference in median annual IBD-related healthcare charges ($10,094 vs $9080; P = .322). CONCLUSIONS: In this first randomized controlled trial of a patient-tailored care coordination intervention, composed of proactive symptom monitoring and care coordinator-triggered algorithms, we observed an improvement in patient symptom scores but not in healthcare charges. Care coordination programs may represent an effective value-based approach to improve symptoms scores without added direct costs in a subgroup of high-risk patients with IBD. (ClinicalTrials.gov, Number: NCT04796571).
BACKGROUND: Inflammatory bowel disease (IBD) is associated with substantial symptom burden, variability in clinical outcomes, and high direct costs. We sought to determine if a care coordination-based strategy was effective at improving patient symptom burden and reducing healthcare costs for patients with IBD in the top quintile of predicted healthcare utilization and costs. METHODS: We performed a randomized controlled trial to evaluate the efficacy of a patient-tailored multicomponent care coordination intervention composed of proactive symptom monitoring and care coordinator-triggered algorithms. Enrolled patients with IBD were randomized to usual care or to our care coordination intervention over a 9-month period (April 2019 to January 2020). Primary outcomes included change in patient symptom scores throughout the intervention and IBD-related charges at 12 months. RESULTS: Eligible IBD patients in the top quintile for predicted healthcare utilization and expenditures were identified. A total of 205 patients were enrolled and randomized to our intervention (n = 100) or to usual care (n = 105). Patients in the care coordinator arm demonstrated an improvement in symptoms scores compared with usual care (coefficient, -0.68, 95% confidence interval, -1.18 to -0.18; P = .008) without a significant difference in median annual IBD-related healthcare charges ($10,094 vs $9080; P = .322). CONCLUSIONS: In this first randomized controlled trial of a patient-tailored care coordination intervention, composed of proactive symptom monitoring and care coordinator-triggered algorithms, we observed an improvement in patient symptom scores but not in healthcare charges. Care coordination programs may represent an effective value-based approach to improve symptoms scores without added direct costs in a subgroup of high-risk patients with IBD. (ClinicalTrials.gov, Number: NCT04796571).
Authors: Siddharth Singh; Joel V Brill; James A Proudfoot; Leanne Metcalfe; Lan Vu; William J Sandborn; Lawrence R Kosinski Journal: Clin Gastroenterol Hepatol Date: 2018-08-24 Impact factor: 11.382
Authors: Julajak Limsrivilai; Ryan W Stidham; Shail M Govani; Akbar K Waljee; Wen Huang; Peter D R Higgins Journal: Clin Gastroenterol Hepatol Date: 2016-09-17 Impact factor: 11.382
Authors: Peter D R Higgins; Gale Harding; Dennis A Revicki; Gary Globe; Donald L Patrick; Kristina Fitzgerald; Hema Viswanathan; Sarah M Donelson; Brian G Ortmeier; Wen Hung Chen; Nancy K Leidy; Kendra DeBusk Journal: J Patient Rep Outcomes Date: 2018-05-30
Authors: Diana Brixner; Manish Mittal; David T Rubin; Philip Mease; Harry H Liu; Matthew Davis; Arijit Ganguli; A Mark Fendrick Journal: Patient Prefer Adherence Date: 2019-09-13 Impact factor: 2.711
Authors: Remo Panaccione; Jean-Frederic Colombel; Simon P L Travis; Peter Bossuyt; Filip Baert; Tomáš Vaňásek; Ahmet Danalıoğlu; Gottfried Novacek; Alessandro Armuzzi; Walter Reinisch; Scott Johnson; Marric Buessing; Ezequiel Neimark; Joel Petersson; Wan-Ju Lee; Geert R D'Haens Journal: Gut Date: 2019-07-08 Impact factor: 23.059
Authors: Peter D R Higgins; Gale Harding; Nancy K Leidy; Kendra DeBusk; Donald L Patrick; Hema N Viswanathan; Kristina Fitzgerald; Sarah M Donelson; Marcoli Cyrille; Brian G Ortmeier; Hilary Wilson; Dennis A Revicki; Gary Globe Journal: J Patient Rep Outcomes Date: 2018-05-09
Authors: Janson Jacob; Daniel Aintabi; Melissa DeJonckheere; Shirley A Cohen-Mekelburg; John I Allen; David N Irani; A Mark Fendrick; Akbar K Waljee; Peter D R Higgins; Jeffrey A Berinstein Journal: Res Social Adm Pharm Date: 2022-06-28